               SEQUENCE LISTING

<110> Clement Bernd

<120> Hemmstoffe von mARC1 zur Behandlung von Krankheiten

<130> K1044PCT

<150> DE102020003608.2
<151> 2020-06-17

<160> 2

<170> BiSSAP 1.3.6

<210> 1
<211> 2258
<212> RNA
<213> Homo sapiens


<220> 
<223> Homo sapiens mitochondrial amidoxime reducing component 1
      (MARC1), mRNA

<400> 1
acagcgccct gcagcgcagg cgacggaagg ttgcagaggc agtggggcgc cgaccaagtg      60

gaagctgagc caccacctcc cactccccgc gccgcccccc agaaggacgc actgctctga     120

ttggcccgga agggttcagg agctgcccag cctttgggct cggggccaaa ggccgcacct     180

tcccccagcg gccccgggcg accagcgcgc tccggccttg ccgccgccac ctcgcggaga     240

agccagccat gggcgccgcc ggctcctccg cgctggcgcg ctttgtcctc ctcgcgcaat     300

cccggcccgg gtggctcggg gttgccgcgc tgggcctgac cgcggtggcg ctgggggctg     360

tcgcctggcg ccgcgcatgg cccacgcggc gccggcggct gctgcagcag gtgggcacag     420

tggcgcagct ctggatctac cctgtgaaat cctgcaaggg ggtgccggtg agcgaggcgg     480

agtgcacggc catggggctg cgcagcggca acctgcggga caggttttgg cttgtgatca     540

accaggaggg aaacatggtt actgctcgcc aggaacctcg cctggtcctg atttccctga     600

cctgcgatgg tgacaccctg actctcagtg cagcctacac aaaggaccta ctactgccta     660

tcaaaacgcc caccacaaat gcagtgcaca agtgcagagt gcacggcctg gagatagagg     720

gcagggactg tggcgaggcc accgcccagt ggataaccag cttcctgaag tcacagccct     780

accgcctggt gcacttcgag cctcacatgc gaccgagacg tcctcatcaa atagcagact     840

tgttccgacc caaggaccag attgcttact cagacaccag cccattcttg atcctttctg     900

aggcgtcgct ggcggatctc aactccaggc tagagaagaa agttaaagca accaacttca     960

ggcccaatat tgtaatttca ggatgcgatg tctatgcaga ggattcttgg gatgagcttc    1020

ttattggtga cgtggaactg aaaagggtga tggcttgttc cagatgcatt ttaaccacag    1080

tggacccaga caccggtgtc atgagcagga aggaaccgct ggaaacactg aagagttatc    1140

gccagtgtga cccttcagaa cgaaagttat atggaaaatc accactcttt gggcagtatt    1200

ttgtgctgga aaacccaggg accatcaaag tgggagaccc tgtgtacctg ctgggccagt    1260

aatgggaacc gtatgtcctg gaatattaga tgccttttaa aaatgttctc aaaaatgaca    1320

acacttgaag catggtgttt cagaactgag acctctacat tttctttaaa tttgtgattt    1380

tcacattttt cgtcttttgg acttctggtg tctcaatgct tcaatgtccc agtgcaaaaa    1440

gtaaagaaat atagtctcaa taacttagta ggacttcagt aagtcactta aatgacaaga    1500

caggattctg aaaactcccc gtttaactga ttatggaata gttctttctc ctgcttctcc    1560

gtttatctac caagagcgca gacttgcatc ctgtcactac cactcgttag agaaagagaa    1620

gaagagaaag aggaagagtg ggtgggctgg aagaatatcc tagaatgtgt tattgcccct    1680

gttcatgagg tacgcaatga aaattaaatt gcaccccaaa tatggctgga atgccacttc    1740

ccttttcttc tcaagccccg ggctagcttt tgaaatggca taaagactga ggtgaccttc    1800

aggaagcact gcagatatta attttccata gatctggatc tggccctgct gcttctcaga    1860

cagcattgga tttcctaaag gtgctcagga ggatggttgt gtagtcatgg aggacccctg    1920

gatccttgcc attcccctca gctaatgacg gagtgctcct tctccagttc cgggtgaaaa    1980

agttctgaat tctgtggagg agaagaaaag tgattcagtg atttcagata gactactgaa    2040

aacctttaaa gggggaaaag gaaagcatat gtcagttgtt taaaacccaa tatctatttt    2100

ttaactgatt gtataactct aagatctgat gaagtatatt ttttattgcc attttgtcct    2160

ttgattatat tgggaagttg actaaacttg aaaaatgttt ttaaaactgt gaataaatgg    2220

aagctacttt gactagtttc agaaaaaaaa aaaaaaaa                            2258


<210> 2
<211> 337
<212> PRT
<213> Homo sapiens


<220> 
<223> MARC1_HUMAN Mitochondrial amidoxime-reducing component 1 Homo
      sapiens

<400> 2
Met Gly Ala Ala Gly Ser Ser Ala Leu Ala Arg Phe Val Leu Leu Ala 
1               5                   10                  15      
Gln Ser Arg Pro Gly Trp Leu Gly Val Ala Ala Leu Gly Leu Thr Ala 
            20                  25                  30          
Val Ala Leu Gly Ala Val Ala Trp Arg Arg Ala Trp Pro Thr Arg Arg 
        35                  40                  45              
Arg Arg Leu Leu Gln Gln Val Gly Thr Val Ala Gln Leu Trp Ile Tyr 
    50                  55                  60                  
Pro Val Lys Ser Cys Lys Gly Val Pro Val Ser Glu Ala Glu Cys Thr 
65                  70                  75                  80  
Ala Met Gly Leu Arg Ser Gly Asn Leu Arg Asp Arg Phe Trp Leu Val 
                85                  90                  95      
Ile Asn Gln Glu Gly Asn Met Val Thr Ala Arg Gln Glu Pro Arg Leu 
            100                 105                 110         
Val Leu Ile Ser Leu Thr Cys Asp Gly Asp Thr Leu Thr Leu Ser Ala 
        115                 120                 125             
Ala Tyr Thr Lys Asp Leu Leu Leu Pro Ile Lys Thr Pro Thr Thr Asn 
    130                 135                 140                 
Ala Val His Lys Cys Arg Val His Gly Leu Glu Ile Glu Gly Arg Asp 
145                 150                 155                 160 
Cys Gly Glu Ala Thr Ala Gln Trp Ile Thr Ser Phe Leu Lys Ser Gln 
                165                 170                 175     
Pro Tyr Arg Leu Val His Phe Glu Pro His Met Arg Pro Arg Arg Pro 
            180                 185                 190         
His Gln Ile Ala Asp Leu Phe Arg Pro Lys Asp Gln Ile Ala Tyr Ser 
        195                 200                 205             
Asp Thr Ser Pro Phe Leu Ile Leu Ser Glu Ala Ser Leu Ala Asp Leu 
    210                 215                 220                 
Asn Ser Arg Leu Glu Lys Lys Val Lys Ala Thr Asn Phe Arg Pro Asn 
225                 230                 235                 240 
Ile Val Ile Ser Gly Cys Asp Val Tyr Ala Glu Asp Ser Trp Asp Glu 
                245                 250                 255     
Leu Leu Ile Gly Asp Val Glu Leu Lys Arg Val Met Ala Cys Ser Arg 
            260                 265                 270         
Cys Ile Leu Thr Thr Val Asp Pro Asp Thr Gly Val Met Ser Arg Lys 
        275                 280                 285             
Glu Pro Leu Glu Thr Leu Lys Ser Tyr Arg Gln Cys Asp Pro Ser Glu 
    290                 295                 300                 
Arg Lys Leu Tyr Gly Lys Ser Pro Leu Phe Gly Gln Tyr Phe Val Leu 
305                 310                 315                 320 
Glu Asn Pro Gly Thr Ile Lys Val Gly Asp Pro Val Tyr Leu Leu Gly 
                325                 330                 335     
Gln 
    

